Special: Over $2,500 Profit in the First Month



SRNE: Sorrento Therapeutics, Inc. is a Sell

The current rating for SRNE is 44, which is 14% below its historic median rating of 50. This indicates higher risk than normal.

The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.